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Background: Although non muscle invasive bladder cancer (NMIBC) generally has a good long-term prognosis, up
to 80% of patients will nevertheless experience local recurrence after the primary tumor resection. The search for
markers capable of accurately identifying patients at high risk of recurrence is ongoing. We retrospectively evaluated
the methylation status of a panel of 24 tumor suppressor genes (TIMP3, APC, CDKN2A, MLH1, ATM, RARB, CDKN2B,
HIC1, CHFR, BRCA1, CASP8, CDKN1B, PTEN, BRCA2, CD44, RASSF1, DAPK1, FHIT, VHL, ESR1, TP73, IGSF4, GSTP1
and CDH13) in primary lesions to obtain information about their role in predicting local recurrence in NMIBC.
Methods: Formaldehyde-fixed paraffin-embedded (FFPE) samples from 74 patients operated on for bladder cancer
were analyzed by methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA): 36 patients
had relapsed and 38 were disease-free at the 5-year follow up. Methylation status was considered as a dichotomous
variable and genes showing methylation ≥20% were defined as “positive”.
Results: Methylation frequencies were higher in non recurring than recurring tumors. A statistically significant
difference was observed for HIC1 (P = 0.03), GSTP1 (P = 0.02) and RASSF1 (P = 0.03). The combination of the three
genes showed 78% sensitivity and 66% specificity in identifying recurrent patients, with an overall accuracy of 72%.
Conclusions: Our preliminary data suggest a potential role of HIC1, GSTP1 and RASSF1 in predicting local
recurrence in NMIBC. Such information could help clinicians to identify patients at high risk of recurrence who
require close monitoring during follow up.
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Although superficial bladder cancer generally has a good
long-term prognosis, up to 80% of patients will have
local recurrence within 5 years of the primary tumor
resection [1]. After transurethral resection of bladder
cancer (TURB), standard follow up involves numerous
cystoscopies with consequently high healthcare costs
and low patient compliance. Multiplicity, tumor size and
prior relapse rate are the only recurrence-related para-
meters currently available for monitoring patients with
bladder cancer [1], but such information would not* Correspondence: w.zoli@irst.emr.it
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stated.seem to be accurate enough to ensure an adequate
follow-up of individuals with stage Ta-T1 non muscle
invasive bladder cancer (NMIBC). It would thus be ex-
tremely useful for clinicians to have new biological
markers that can predict recurrence more accurately.
The role of epigenetic alterations in the carcinogenesis
of solid tumors has been intensively investigated over the
last ten years [2,3]. DNA methylation at CpG rich regions
often occurs at tumor suppressor gene promoters, fre-
quently producing a reduction in the expression of target
genes. An increasing number of papers are being pub-
lished on the role of gene methylation and its potential
clinical application in human tumors [4]. Methylation
seems to be an early event in the development of a num-
ber of solid tumors including bladder cancer [5,6] and canl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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http://www.jeccr.com/content/32/1/94thus be regarded as an early sign of cancer before the
disease becomes muscle-invasive. Methylated tumor sup-
pressor genes such as APC, RARB2, BRCA1 have recently
been indicated as valid diagnostic markers for NMIBC
[7-10]. A number of papers have also focused on the role
of methylation as a prognostic marker, but it is not clear
which methylated genes can accurately predict recurrence.
Some studies have hypothesized hypermethylation of
tumor suppressor genes, such as TIMP3, as a good prog-
nostic marker [11,12], while others have indicated hyper-
methylated E-cadherin, p16, p14, RASSF1, DAPK, APC,
alone or in different combinations, as potential markers of
early recurrence and poor survival [13-15].
In the present study we evaluated the methylation
status of a panel of 24 genes (TIMP3, APC, CDKN2A,
MLH1, ATM, RARB, CDKN2B, HIC1, CHFR, BRCA1,
CASP8, CDKN1B, PTEN, BRCA2, CD44, RASSF1,
DAPK1, FHIT, VHL, ESR1, TP73, IGSF4, GSTP1 and
CDH13) in superficial bladder cancer to determine theira)
b)
Figure 1 Electropherogram relating to a) undigested and b) digested HT1376 samples with methylation of APC and RASSF1 genes.
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some of these genes has already been investigated in
bladder cancer [11-15], its relevance as an indicator of
recurrence has yet to be confirmed. We used the rela-
tively new methodology of methylation specific multiplex
ligation dependent probe amplification (MS-MLPA) to
evaluate epigenetic gene profiles. This approach permits
methylation analysis of multiple targets in a single ex-
periment [16,17] and has been successfully used to evalu-
ate the diagnostic or prognostic relevance of different
markers in several tumor types such as lung [18], rectal
[19], breast [20] and recently, bladder cancers [7,8].
Methods
Case series (retrospective cohort study)
Tissue samples from 74 patients (65 males, 9 females)
submitted to transurethral resection of primary bladder
cancer at the Department of Urology of Morgagni-
Pierantoni Hospital in Forlì between 1997 and 2006 were
used for the study. All samples were retrieved from the
archives of the Pathology Unit of the same hospital.
Median age of patients was 73 years (range 39–92): 31
were <70 years and 43 ≥70 years. On the basis of 2004
World Health Organization criteria, final diagnosis wasTable 2 Summary of gene function and chromosomal localiza
Gene
TIMP metallopeptidase inhibitor 3 (TIMP3)
Adenomatous polyposis coli (APC)
cyclin-dependent kinase inhibitor 2A (CDKN2A)
MutL homolog 1, colon cancer, nonpolyposis type 2 (MLH1)
Ataxia telangiectasia mutated (ATM)
Retinoic acid receptor, beta (RARB) C
Hypermethylated in Cancer 1(HIC1)
Checkpoint with forkhead and ring finger domains (CHFR)
breast cancer 1, early onset (BRCA1)
Caspase 8, apoptosis-related cysteine peptidase (CASP8)
Cyclin-dependent kinase inhibitor 1B (CDKN1B)
Phosphatase and tensin homolog (PTEN)
Breast cancer 2, early onset (BRCA2)
CD44 molecule (Indian blood group) (CD44)
Ras association (RalGDS/AF-6) domain family member 1 (RASSF1)
Death-associated protein kinase1 (DAPK)
Von Hippel-Lindau tumor suppressor (VHL)
Estrogen receptor 1 (ESR1) C
Tumor protein p73 (TP73) A
Fragile histidine triad gene (FHIT)
Cell adhesion molecule 1 (IGSF4 (CADM1))
Cadherin 13, H-cadherin (heart) (CDH13)
Glutathione S-transferase pi 1 (GSTP1)low grade non muscle invasive bladder cancer (NMIBC)
in 55 patients and high grade NMIBC in 19 patients. At
a median follow up of 5 years 38 patients were still
disease-free and 36 had experienced one or more epi-
sodes of local recurrence. In this retrospective study,
the two subgroups (disease free or relapsed) of patients
were equally distributed for sex, age, grade and stage
(Table 1).
All patients gave written informed consent for bio-
logical samples to be used for research purposes. The
study protocol was reviewed and approved by the ‘Area
Vasta’ Istituto Scientifico Romagnolo per lo Studio e la
Cura dei Tumori (IRST) Ethics Committee.
Macrodissection and DNA isolation
Five 5-μm-thick sections were obtained from each
paraffin-embedded block. Macrodissection was performed
on hematoxylin-eosin stained sections and only cancer tis-
sue was used for DNA isolation. Genomic DNA was puri-
fied using QIAmp DNA FFPE Tissue (Qiagen, Milan),
according to the manufacturer’s instructions.
DNA was also isolated from a human bladder cancer
cell line (HT1376) using Qiamp DNA minikit (Qiagen,
Milan, Italy), according to the manufacturer’s instructions.tion
Function Chromosomal localization
Invasion and metastasis 22q12.3
WNT antagonist 5q22
Cell-cycle control gene 9p21
DNA mismatch repair 3p22.1
Cell-cycle control gene 11q23
ell differentiation and proliferation 3p24.2
Putative tumor suppressor gene 17p13.3
Putative tumor suppressor gene 12q24.33
Maintenant of genomic stability 17q21.31
Apoptosis related gene 2q33.2
Cell-cycle control gene 12p13.2
Cell-cycle regulation gene 10q23.3
Maintenance of genomic stability 13q12.3
Cell-cell interaction mediator 11p12
Putative tumor suppressor gene 3p21.3
Apoptosis-related gene 9q34.1
Putative tumor suppressor gene 3p25
ell differentiation and proliferation 6q25.1
poptotic response to DNA damage 1p36.32
Putative tumor suppressor gene 3p14.2
Cell adhesion related gene 11q23
Cell invasion 16q23.3
DNA damage repair gene 11q13
Table 3 Methylation frequencies of different genes in the





tumors (n = 38)
Recurrent
tumors (n = 36)
P value*
CD44 1 18 3 0.06
CASP8 1 3 0 1
MLH1
(locus 2)
1 3 0 1
PTEN 3 5 0 0.49
VHL 3 5 0 0.49
BRCA1 4 8 0 0.24
CHFR 4 5 3 1
ATM 5 8 3 0.62
BRCA2 5 8 3 0.62
CDKN1B 5 5 5 1
RARB 6 8 6 1
HIC1 9 16 0 0.03
FHIT 10 1 10 1
MLH1
(locus 1)
11 15 8 0.48
ESR1 12 16 6 0.26
TIMP3 13 18 8 0.31
TP73 14 19 8 0.19
CDKN2A 14 16 14 1
GSTP1 15 26 5 0.02
DAPK 17 24 8 0.11
IGSF4
(CADM1)
21 18 25 0.58
RASSF1
(locus 1)
23 29 14 0.16
APC 29 34 25 0.45
RASSF1
(locus2)
33 45 19 0.03
CDH13 50 53 47 0.81
*Fisher’s exact test 2-tailed P value (difference between recurrent and non
recurrent tumors). Significant genes are highlighted as bold data.
Casadio et al. Journal of Experimental & Clinical Cancer Research 2013, 32:94 Page 4 of 9
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(MS-MPLA)
MS-MLPA was performed using at least 50 ng of
genomic DNA dissolved in 1XTE buffer (Promega,
Madison, WI, USA). DNA isolated from HT 1376 cell
line was used as internal control for MS MLPA analysis
(Figure 1). The methylation status of 24 tumor suppres-
sor gene promoters was analyzed using the ME001C1 kit
(MRC-Holland, Amsterdam, The Netherlands) (Table 2).
Two different probes that recognize two different sites
of the promoter region were used for genes RASSF1 and
MLH. We excluded CDKN2B gene from the analysis be-
cause its probe is sensitive to improper Hha1 digestion
in FFPE samples. In brief, DNA was denatured (10 min
at 98°C) and cooled at 25°C, after which the probe mix
was added to the samples and hybridization was per-
formed by incubation at 60°C for 16–18 h. The reaction
was divided equally in two vials, one for ligation and the
other for ligation-digestion reaction for each tumor. We
added a mix composed of Ligase-65 buffer, Ligase-65 en-
zyme and water to the first vial and a mix of Ligase-65
Buffer, Ligase 65 enzyme, Hha1 enzyme (Promega, UK)
and water to the second. The samples were then incu-
bated at 49°C for 30 min. At the end of the ligation and
ligation-digestion reactions, samples were amplified by
adding a mix of PCR buffer, dNTPs and Taq polymerase.
The PCR reaction was performed under the following
conditions: 37 cycles at 95°C for 30 sec, 60°C for 30 sec
and 72°C for 60 sec. The final incubation was performed
at 73°C for 20 min.
Amplification products were analyzed by ABI-3130
genetic Analyzer (Applied Biosystem, UK). Universally
methylated and unmethylated genomic DNA was used
as positive or negative control, respectively.
Electropherograms obtained were analyzed using Gene
Mapper software (Applied Biosystem, UK) and the peak
areas of each probe were exported to a home-made excel
spreadsheet. In accordance with the manufacturer’s
instructions, we carried out “intrasample data normaliza-
tion” by dividing the signal of each probe by the signal of
every reference probe in the sample, thus creating as many
ratios per probe as there were reference probes. We then
calculated the median value of all probe ratios per probe,
obtaining the normalization constant (NC). Finally,
the methylation status of each probe was calculated
by dividing the NC of a probe in the digested sample
by the NC of the same probe in the undigested
sample, and by multiplying this ratio by 100 to have
a percentage value, as follows:
NC digested sampleð Þ
NC undigested sampleð Þ  100MS-MLPA technique reproducibility was assessed by
performing three independent methylation profile analyses
on a bladder cell line (HT1376). The methylation level for
each gene was found to be the same in each experiment.
We considered the promoters showing a ratio ≥0.20 as
methylated, while those with a ratio <0.20 were regarded
as unmethylated. The cut-off was chosen on the basis of
experiments performed on the bladder cancer cell line
(HT1376) and on data from the literature [21,22]. We
have also performed the analysis on some samples from
healthy tissues, to confirm that the background noise
was inferior to 0.20 cut-off, such excluding false positive
results due to experimental procedure.
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Fisher’s exact test was used to compare the frequency of
promoter methylation in the two subgroups: recurrent
tumors versus non recurrent tumors. Methylation status
was considered as a dichotomic variable and genes
showing methylation ≥ 20% were classified as positive. A
difference was considered significant if it showed a two-
tailed P value ≤0.05. The genes showing a significant
p value in Fisher’s exact test were used to analyze the
methylator phenotype. Study endpoints were sensitivity
(the proportion of recurrent cancer patients who were
correctly identified by the test or procedures) and speci-
ficity (the proportion of non recurrent cancer patients
who were correctly identified), with their 95% confi-
dence intervals (CIs). We also evaluated overall accu-
racy, defined as the proportion of the total number of
patients correctly identified by the test.
The student’s T test was used to assess the methylation
index (MI), which was considered as a continuous
variable. Logistic regression analysis was performed
using the Epicalc of R to evaluate the performance of a
panel of gene promoters (HIC1, RASSF1 and GSTP1) in
discriminating between recurrent and non recurrent pa-
tients. We created logistic regression models with
methylation levels of the three gene promoters (HIC1,
RASSF1 and GSTP1). Probabilities were calculated as
follows: P = exp ((Σ(bixi) + c)/(1 + Σ(bixi) + c), where p is






















Figure 2 Methylation levels of the three significant genes (HIC1, RASScoefficient of a given gene, x is the log2-transformed
methylation level and c is a constant generated by the
model. The ROCR package was used to obtain the ROC
curves of the models and area under the curve (AUC)
values. Recurrence-free survival was analyzed with the
Log-rank test using SAS 9.3 software. All the molecular
analyses were performed in a blind manner.
Results
MS-MLPA analysis was feasible in all samples. The
methylation frequency in the overall series varied widely
(1% to 50%) for the different genes (Table 3). A separate
analysis as a function of recurrence showed lower gene
methylation in recurring than non recurring tumors,
with the exception of CDKN1B, FHIT and IGSF4 genes.
However, a significant difference between recurrent and
non recurrent tumors was only observed for GSTP1, HIC1
and RASSF1 locus 2 (Table 3), with lower methylation in
relapsed than non relapsed patients (Figure 2). The
methylation index (MI), evaluated as the number of meth-
ylated genes relative to the total number of analyzed
genes, showed values from 0 to 0.68 in the overall series
of 23 genes and a significantly lower median value in non
recurrent (0.08) than recurrent (0.12) (P = 0.011) patients
(Table 4). To reduce the complexity of the methodological
approach, further analysis was limited to a series of 10
genes (GSTP1, HIC1, RASSF1-locus2, CD44,DAPK,




F1, GSTP1) showed as box plot.
Table 4 Methylation index analyisis
Median value P value
Methylation
index (MI)
Overall Recurrence No recurrence
23 Genes* 0.1 0.08 0.12 0.011
10 Genes** 0.2 0 0.2 0.0007
*MI = Number of methylated genes/number of analyzed genes.
**MI=number of methylated genes/ 10 genes (GSTP; HIC1; RASSF1 (LOCUS 1);
RASSF1 (LOCUS 2); CD44; DAPK; TP73; BRCA1; ESR; TIMP3).
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nificance (P values varying from 0.02 to 0.31). Again, a
higher median MI was seen in patients who relapsed com-
pared to those who did not (0 versus 0.2; P = 0.0007)
(Table 4).
We constructed a prognostic algorithm with the 3 sig-
nificant genes (GSTP1, HIC1 and RASSF1) considering
two phenotypes: the “methylated phenotype” (MP) (sam-
ples with at least one of the three genes methylated), and
the “unmethylated phenotype” (samples with none of the
three genes methylated). Of the 33 patients with methy-
lated phenotype, 25 (76%) were still disease-free and
8 (24%) had had at least one intravescical recurrence at
a median follow up of 5 years (Figure 3). Conversely, of
the 41 patients with unmethylated phenotype, 28 (68%)
had relapsed within 5 years of surgery and 13 (32%) hadFigure 3 Prognostic algorithm with the three significant genes (GSTP
recurrent tumors with unmethylated HIC1, RASSF1, GSTP1 relative to the tot
the number of non recurrent tumors with methylated phenotype relative t
was calculated as the number of correctly classified tumors relative to theremained disease-free. The three-gene panel showed
78% sensitivity in identifying recurrent tumors and 66%
specificity, with an overall accuracy of 72%.
We also performed ROC curve analysis for the three
significant genes, singly or in combination, considered as
continuous variables. Resultant AUCs were 0.5917 for
HIC1, 0.6725 for RASSF1 and 0.5409 for GSTP1, the
best AUC (0.6959) reached for the combination of the
three genes (Figure 4).
Recurrence-free survival analysis of patients with
methylated or unmethylated tumors highlighted a signi-
ficantly higher recurrence-free survival (P = 0.0019) for
those whose tumors showed the methylated phenotype
(Figure 5).
The recurrence free survival analysis performed consi-
dering only the recurrent patients, showed that patients
with unmethylated tumors had a lower median recurrent
free survival time (14.5 months), with the respect to
patients with methylated ones (18 months). However, the
two subgroups are not equal distributed to give a statis-
tical significant result (P = 0.9392, data not shown).
Multivariable analysis considering clinical and biolo-
gical parameters (patient age and sex; tumor grade, stage
and size; tumor multiplicity, methylated phenotype)
showed that only age and methylated phenotype were
independent predictors of recurrence. Specifically, patients1, HIC1 and RASSF1). Sensitivity was evaluated as the number of
al number of recurrent tumors analyzed. Specificity was evaluated as
o the total number of non recurrent tumors analyzed. Overall accuracy
total number of analyzed tumors.
HIC1+RASSF1+GSTP1= MP








Figure 4 ROC curves relating to the three significant genes (HIC1,RASSF1, GSTP1) analyzed singly or in combination.
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relapsing than older ones (P = 0.028) and their methyla-
tion phenotype was significantly predictive of recurrence
(P < 0.0001).
Discussion
The present study focused on evaluating the methylation
status of tumor suppressor genes and on verifying its
role in predicting recurrence of non muscle invasive
bladder cancer (NMIBC). The MS-MLPA technique has
the advantage of requiring only a small quantity of
DNA, is capable of rapidly determining the methylation
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Figure 5 Recurrence-free survival in patients with methylated
phenotype (samples with at least one of the three significant
genes methylated) or unmethylated phenotype (samples with
none of the three genes methylated).has also been shown to work well in formalin-fixed
paraffin-embedded samples. However, an important
limitation of our study was the lack of a sufficient quan-
tity of cancer tissue to confirm the methylation results
using a second technique such as methylation specific
PCR (MS PCR) or gene expression analyses.
In agreement with results from other studies [18], we
found a positive correlation between gene methylation
and lack of recurrence, highlighting that putative tumor
suppressor genes do not always act as tumor suppressors
but may actually have different biological functions.
Statistical analysis revealed 3 genes (HIC1, GSTP1,
and RASSF1) capable of significantly predicting tumor
recurrence. Their methylation was significantly indica-
tive of a lack of recurrence at the 5-year follow up. The
combined analysis of the three genes showed 72% accu-
racy in predicting recurrence or non recurrence.
HIC1 is a new candidate tumor suppressor gene [23],
but the relevance of its methylation in bladder cancer
prognosis is still unknown. Although GSTP1 methy-
lation is a well known event in the carcinogenesis of
prostate cancer, its role in bladder carcinoma has yet to
be defined. A recent study by Pljesa-Ercegovac and
coworkers [24] revealed that high GSTP1 expression is
associated with an altered apoptotic pathway and
bladder cancer progression. As methylation reduces gene
expression, our data are in agreement with those of
Pljesa-Ercegovac, the absence of GSTP1 methylation
observed in our study supporting the hypothesis of more
aggressive behavior of bladder tumors and consequently
of a higher relapse rate.
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development is still unclear, Ha and coworkers reported
that its methylation would seem to play a part in pre-
dicting recurrence in low grade and stage bladder tumors
[25]. Surprisingly, we observed lower methylation levels of
RASSF1 in recurrent tumors than in non recurrent
ones, the discordance possibly due to different tech-
niques used.
The MS-MLPA approach only permitted us to analyze
one CpG site per probe, whereas several CpG sites may
have been evaluated by Ha using the MS PCR tech-
nique [25]. For these reasons, we believe that further
evaluation is needed to clarify the role of RASSF1 in
bladder cancer, especially with regard to the cor-
relation between its methylation status and protein
expression.We also observed fairly low methylation
frequencies for all the loci analyzed compared to
those reported in other papers [26]. Such disagree-
ment could, again, be due to the different analytical
techniques adopted and/or to the different case series
analyzed. Methylation cannot be the only mechanism
of recurrence of NMIBC because the behavior of
bladder tumors is fairly heterogeneous, as shown by
Serizawa and coworkers [27] who observed an inverse
correlation between FGFR mutations and hypermethy-
lation events. In their study of the mechanisms of
NMIBC recurrence, Bryan and coworkers [28], identi-
fied four reasons for relapse: incomplete resection,
tumor cell re-implantation, growth of microscopic tu-
mors and new tumor formation. These mechanisms
differ greatly from each other and the identification
of a single marker that is common to all four mecha-
nisms appears improbable. It is more likely that a
molecular marker characterizes tumor recurrence as a
result of the third or fourth mechanisms, which may
involve molecular alterations. This might explain why
accuracy in our study only reached 72%.Conclusions
Our preliminary findings pave the way for in depth
evaluation of the methylation levels of HIC1, GSTP1,
and RASSF1 genes in larger case series to improve the
clinical surveillance of patients with superficial bladder
cancer.Consent
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